PharmGen Science Inc (004720) — Cash Flow-to-Debt Ratio
PharmGen Science Inc (004720) has a Cash Flow-to-Debt Ratio of 0.02x as of September 2025, meaning its operating cash flow of ₩1.91 Billion could theoretically repay 0% of its total liabilities (₩83.70 Billion) in one year. See 004720 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
PharmGen Science Inc Cash Flow-to-Debt Ratio (2011–2024)
Historical debt coverage capacity for PharmGen Science Inc across 13 annual periods. For the full cash flow conversion analysis, see 004720 operating cash flow.
Annual Cash Flow-to-Debt Ratio for PharmGen Science Inc (2011–2024)
Year-by-year debt coverage analysis for PharmGen Science Inc. Check 004720 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.02x | ₩2.38 Billion | ₩114.02 Billion | ▼ -58.6% |
| 2023 | 0.05x | ₩5.44 Billion | ₩107.71 Billion | ▲ +533.0% |
| 2022 | -0.01x | ₩-1.29 Billion | ₩110.28 Billion | ▼ -114.0% |
| 2021 | 0.08x | ₩7.78 Billion | ₩93.39 Billion | ▲ +61.9% |
| 2020 | 0.05x | ₩2.68 Billion | ₩51.97 Billion | ▼ -10.7% |
| 2019 | 0.06x | ₩2.52 Billion | ₩43.79 Billion | ▼ -43.5% |
| 2018 | 0.10x | ₩4.22 Billion | ₩41.35 Billion | ▼ -3.3% |
| 2017 | 0.11x | ₩1.84 Billion | ₩17.43 Billion | ▼ -62.1% |
| 2016 | 0.28x | ₩7.75 Billion | ₩27.89 Billion | ▲ +36.6% |
| 2015 | 0.20x | ₩3.62 Billion | ₩17.79 Billion | ▲ +321.3% |
| 2014 | -0.09x | ₩-2.02 Billion | ₩21.93 Billion | ▲ +66.1% |
| 2013 | -0.27x | ₩-4.20 Billion | ₩15.49 Billion | ▼ -326.3% |
| 2011 | 0.12x | ₩2.89 Billion | ₩24.13 Billion | — |